Hypomethylating agent versus venetoclax combination: an electronic health records-based target trial emulation among Asian elderly patients with newly diagnosed acute myeloid leukaemia in Hong Kong.

Ther Adv Hematol · 2025 · PMC12227900 · PMID 40620728

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a significant trendno p-value reported

There was a significant trend towards increased prescription of combination and decreased prescription of monotherapy from 2018 to 2023 ( Figure 2 ).

also in 9,775 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.